|
시장보고서
상품코드
2079833
혈장 유래 의약품 시장 : 시장 규모, 점유율 및 성장 분석 - 제품 유형별, 용도별, 투여 경로별, 최종 사용자별, 환자층별, 유통 채널별, 지역별 업계 예측(2026-2033년)Plasma Derived Medicine Market Size, Share, and Growth Analysis, By Product Type, By Application, By Route of Administration, By End User, By Patient Group, By Distribution Channel, By Region - Industry Forecast 2026-2033 |
||||||
세계의 혈장 유래 의약품 시장 규모는 2024년에 403억 달러로 평가되었고, 2025년 431억 6,000만 달러에서 2033년까지 747억 2,000만 달러로 확대될 전망이며, 예측 기간(2026-2033년) CAGR 7.1%로 성장할 전망입니다.
주로 면역글로불린, 응고 인자, 알부민 등의 치료용 단백질에 힘입어 성장하고 있는 전 세계 혈장 유래 의약품 시장은 특히 기존 의약품으로는 충분히 대응할 수 없는 희귀 출혈성 질환이나 면역 결핍증의 치료에 있어 지극히 중요한 역할을 하고 있습니다. 이 분야는 이러한 의약품의 안전성 프로파일을 개선하는 기술적 진보 덕분에 주목을 받고 있습니다. 현재 약 300억 달러 규모의 이 시장은 혈우병 진단 건수 증가, 면역 지원이 필요한 고령화 사회의 진전, 그리고 혈장 요법에 대한 인식 제고에 힘입어 성장을 이어가고 있습니다. 의료 종사자들이 재조합 제제에 비해 혈장 유래 응고 인자의 장점을 인식함에 따라, 병원의 조달량은 증가할 것으로 예측됩니다. 또한, 팬데믹 회복기 혈장 요법 등 새로운 용도 역시 시장의 확대와 다양화에 한층 더 기여하고 있습니다.
세계 혈장 유래 의약품 시장의 성장 요인
의료 종사자들이 안전성을 확보하면서 면역 반응을 효과적으로 조절하는 치료법을 모색하는 가운데, 면역 요법에 대한 수요 증가가 혈장 유래 의약품 시장의 확장을 크게 뒷받침하고 있습니다. 혈장 단백질이 수동 면역을 제공하고 염증을 조절하는 능력은 자가면역 질환 및 감염증 발생률 증가와 맞물려, 의료 시스템이 이러한 생물학적 제제를 치료 프로토콜에 포함하도록 촉진하고 있습니다. 그 결과, 각 제약사는 임상적 요건을 충족하기 위해 조사 활동을 강화하고 전략적 제휴를 맺고 있습니다. 이러한 추세는 시장의 성장을 뒷받침하고, 다양한 치료 분야에서 광범위한 도입을 촉진하며, 궁극적으로는 환자 치료와 치료 성과 향상으로 이어집니다.
세계 혈장 유래 의약품 시장의 제약 요인
세계 혈장 유래 의약품 시장의 성장은 까다로운 임상 검증 요건을 부과하는 엄격한 규제 승인 절차로 인해 현저히 저해되고 있습니다. 당국은 확실한 안전성 및 유효성 데이터의 제출을 의무화하고 있으며, 이로 인해 개발 기간이 길어지고 제조업체의 자원 투입이 확대되고 있습니다. 여러 단계의 임상시험과 방대한 문서 작성이 필요하다는 점은 필요한 풍부한 자원을 갖추지 못한 중소기업에게 장벽이 되고 있으며, 그 결과 시장에 진입할 가능성이 있는 기업의 수가 줄어들고 있습니다. 이로 인해 제품 파이프라인의 지연이나 투자 결정의 신중화를 초래하게 되며, 전 세계적으로 치료 수요가 지속되고 있음에도 불구하고, 결국 시장 전체의 성장을 저해하게 될 것입니다.
세계의 혈장 유래 의약품 시장 동향
세계의 혈장 유래 의약품 시장은 맞춤형 면역 요법에 대한 수요 증가에 힘입어 눈부신 성장을 이루고 있습니다. 각 제약사는 환자별로 맞춤화된 혈장 유래 면역글로불린과 특정 질환의 특징을 효과적으로 표적으로 삼는 맞춤형 항체 칵테일의 개발에 주력하고 있습니다. 유전체 프로파일링 및 첨단 바이오프로세싱 분야의 혁신을 활용함으로써, 각 기업은 암, 자가면역 질환, 감염병을 대상으로 한 치료법의 임상적 유효성을 높이고 있습니다. 이러한 추세에 따라 기업들은 광범위한 연구개발(R&D) 제휴에 대한 투자를 확대하고 있으며, 보다 유연한 소량 생산에 대응할 수 있도록 제조 공정을 조정하고 있습니다. 그 결과, 이러한 움직임은 제품 포트폴리오의 재구성을 촉진하고, 헬스케어 분야에서 첨단 치료법의 도입을 가속화하고 있습니다.
자주 묻는 질문
목차
서론
조사 방법
주요 요약
시장 역학 및 전망
주요 시장 인사이트
세계의 혈장 유래 의약품 시장 규모 : 제품 유형별
세계의 혈장 유래 의약품 시장 규모 : 용도별
세계의 혈장 유래 의약품 시장 규모 : 투여 경로별
세계의 혈장 유래 의약품 시장 규모 : 최종 사용자별
세계의 혈장 유래 의약품 시장 규모 : 환자 그룹별
세계의 혈장 유래 의약품 시장 규모 : 유통 채널별
세계의 혈장 유래 의약품 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론 및 제안
AJY 26.07.13Global Plasma Derived Medicine Market size was valued at USD 40.3 Billion in 2024 and is poised to grow from USD 43.16 Billion in 2025 to USD 74.72 Billion by 2033, growing at a CAGR of 7.1% during the forecast period (2026-2033).
The global plasma-derived medicines market, primarily driven by therapeutic proteins like immunoglobulins, coagulation factors, and albumin, plays a crucial role in treating rare bleeding disorders and immune deficiencies, particularly where conventional drugs fall short. This sector has gained traction due to technological advances that enhance the safety profiles of these medicines. Currently valued at approximately $30 billion, the market is experiencing growth fueled by rising diagnoses of hemophilia, an aging population necessitating immune support, and greater awareness of plasma therapies. As medical professionals recognize the benefits of plasma-derived clotting factors over recombinant alternatives, hospitals are likely to increase their procurement volumes. Additionally, emerging applications such as convalescent plasma therapy during pandemics further contribute to market expansion and diversification.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Plasma Derived Medicine market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Plasma Derived Medicine Market Segments Analysis
Global plasma derived medicine market is segmented by product type, application, route of administration, end user, patient group, distribution channel and region. Based on product type, the market is segmented into Immunoglobulins, Coagulation Factors, Albumin, Alpha-1 Proteinase Inhibitors, Hyperimmune Globulins and Others. Based on application, the market is segmented into Immunodeficiency Disorders, Hemophilia, Neurological Disorders, Critical Care & Trauma, Infectious Diseases and Others. Based on route of administration, the market is segmented into Intravenous, Subcutaneous and Intramuscular. Based on end user, the market is segmented into Hospitals, Specialty Clinics, Infusion Centers and Home Healthcare Settings. Based on patient group, the market is segmented into Pediatric, Adult and Geriatric. Based on distribution channel, the market is segmented into Hospital Pharmacies, Specialty Pharmacies and Retail Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Plasma Derived Medicine Market
The growing demand for immunotherapies is significantly propelling the expansion of the plasma-derived medicines market, as healthcare providers search for treatments that effectively modulate immune responses while ensuring safety. Plasma proteins' capacity to offer passive immunity and manage inflammation corresponds with the increasing incidence of autoimmune and infectious diseases, prompting healthcare systems to integrate these biologics into their treatment protocols. As a result, pharmaceutical companies are intensifying their research efforts and forming strategic partnerships to fulfill clinical requirements. This dynamic reinforces market growth and encourages widespread adoption across various therapeutic sectors, ultimately enhancing patient care and outcomes.
Restraints in the Global Plasma Derived Medicine Market
The expansion of the Global Plasma Derived Medicine market is significantly hindered by stringent regulatory approval processes that impose demanding clinical validation requirements. Authorities necessitate robust safety and efficacy data, which extends development timelines and escalates resource commitments for manufacturers. The need for multiple trial phases and extensive documentation serves as a barrier for smaller companies that lack the vast resources needed, thereby diminishing the number of potential market entrants. This results in delays in product pipelines and leads to more cautious investment decisions, ultimately constraining overall market growth, even in the face of persistent therapeutic demand on a global scale.
Market Trends of the Global Plasma Derived Medicine Market
The Global Plasma Derived Medicine market is experiencing significant growth driven by the increasing demand for personalized immunotherapies. Manufacturers are focusing on developing patient-specific plasma-derived immunoglobulins and customized antibody cocktails that effectively target distinct disease signatures. By leveraging innovations in genomic profiling and advanced bioprocessing, companies are enhancing the clinical efficacy of therapies aimed at oncology, autoimmune disorders, and infectious diseases. This trend is prompting firms to invest in extensive R&D collaborations and adapt manufacturing processes for more flexible, small-batch production. Consequently, this dynamic is reshaping product portfolios and accelerating the adoption of advanced therapies within the healthcare landscape.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
- Disease Epidemiology
Global Plasma Derived Medicine Market Size by Product Type & CAGR (2026-2033)
- Market Overview
- Immunoglobulins
- Coagulation Factors
- Albumin
- Alpha-1 Proteinase Inhibitors
- Hyperimmune Globulins
- Others
Global Plasma Derived Medicine Market Size by Application & CAGR (2026-2033)
- Market Overview
- Immunodeficiency Disorders
- Hemophilia
- Neurological Disorders
- Critical Care & Trauma
- Infectious Diseases
- Others
Global Plasma Derived Medicine Market Size by Route of Administration & CAGR (2026-2033)
- Market Overview
- Intravenous
- Subcutaneous
- Intramuscular
Global Plasma Derived Medicine Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Specialty Clinics
- Infusion Centers
- Home Healthcare Settings
Global Plasma Derived Medicine Market Size by Patient Group & CAGR (2026-2033)
- Market Overview
- Pediatric
- Adult
- Geriatric
Global Plasma Derived Medicine Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Specialty Pharmacies
- Retail Pharmacies
Global Plasma Derived Medicine Market Size & CAGR (2026-2033)
- North America (Product Type, Application, Route of Administration, End User, Patient Group, Distribution Channel)
- US
- Canada
- Europe (Product Type, Application, Route of Administration, End User, Patient Group, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Product Type, Application, Route of Administration, End User, Patient Group, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Product Type, Application, Route of Administration, End User, Patient Group, Distribution Channel)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Product Type, Application, Route of Administration, End User, Patient Group, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- CSL Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Grifols, S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Kedrion Biopharma Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Octapharma AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- China Biologic Products Holdings, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- LFB S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biotest AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GC Biopharma Corp.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Shanghai RAAS Blood Products Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- ADMA Biologics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Intas Pharmaceuticals Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- SK Plasma Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bharat Serums and Vaccines Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Kamada Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Hualan Biological Engineering Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanquin Plasma Products B.V.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- PlasmaGen Biosciences Pvt. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Reliance Life Sciences Pvt. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
